NUST Institutional Repository

In vivo Testing of Anticancerous and Antidepressant Agent Silymarin Against Glioblastoma Multiforme

Show simple item record

dc.contributor.author Akhtar, Aimen
dc.contributor.author Fatima, Hadia
dc.contributor.author Sajjad, Sania
dc.contributor.author Sabir, Sara
dc.date.accessioned 2023-07-10T09:48:54Z
dc.date.available 2023-07-10T09:48:54Z
dc.date.issued 2023
dc.identifier.issn 323841
dc.identifier.uri http://10.250.8.41:8080/xmlui/handle/123456789/34522
dc.description Supervisor : Dr. Aneela Javed en_US
dc.description.abstract Glioblastoma multiforme (GBM) is a highly malignant grade IV astrocytoma comprising 54% of all glial cell tumors, with a median survival age of less than 12 months. It is characterized by cognitive decline, seizures, and development of major depressive disorder (MDD). Limited treatment options, lower efficacy of drugs to cross the blood brain barrier (BBB), emerging resistance against the standard treatment drug temozolomide (TMZ), and aggravation of MDD symptoms by TMZ present the need to develop novel treatment strategies. This study aimed to investigate the anticancer and antidepressant potential of silymarin (SIL) in an orthotopic GBM xenograft mouse model. The mouse model was constructed by injecting U-87 cells into the prefrontal cortex of the brain. Mice were divided into 8 groups (4 control and 4 GBM induced group), and were treated with normal saline, Temozolomide (TMZ), Fluoxetine (FLX) standard antidepressant and targeted compound Silymarin (SIL). Treatment doses were administered intraperitoneally. Six behavioral tests evaluating behavioral despair, anhedonia, anxiety, depression-like behavior, locomotion, and social interaction were conducted to evaluate the therapeutic effects of the drugs. TMZ elevated depression-like behavioral symptoms in both the control and GBM groups in all six experiments. Silymarin did not induce any depressive symptoms and proved to be effective in alleviating anxiety- and depression-like behaviors associated with GBM in all six experiments, showing greater efficacy than the standard antidepressant FLX. Moreover, Silymarin reduced inflammation in the GBM group. Thus, the efficacy of silymarin merits further molecular studies, and utilizing silymarin in combinatorial therapy could prove pivotal in the fight against GBM and other cancers en_US
dc.language.iso en en_US
dc.publisher Atta Ur Rahman School of Applied Biosciences (ASAB), NUST en_US
dc.subject Anxiety, Astrocytoma, Fluoxetine, Glioblastoma Multiforme, Major Depressive Disorder, Radiation therapy, Seizures, Silymarin , Temozolomide en_US
dc.title In vivo Testing of Anticancerous and Antidepressant Agent Silymarin Against Glioblastoma Multiforme en_US
dc.type Thesis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account